Rechercher | Friends - Best Social Network - החברים

Sindhuri Kotamraju Ajouter une nouvelle offre d'emploi Health
2025-07-17 12:28:06

How MASH is Shaping the Future of Liver Disease
Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as Non-Alcoholic Steatohepatitis (NASH), is quickly emerging as a major global health concern. Closely linked to metabolic conditions such as obesity, type 2 diabetes, and insulin resistance, MASH represents a progressive form of fatty liver disease that can lead to serious complications like liver cirrhosis, failure, or...

0 Commentaires 0 Parts 489 Vue 0 Aperçu

Connectez-vous pour aimer, partager et commenter!
Devidi Jahnavi Ajouter une nouvelle offre d'emploi Health
2025-06-17 07:37:44

Resmetirom Approval Marks a Milestone in MASH Treatment
Metabolic Dysfunction-Associated Steatohepatitis (MASH), previously known as Nonalcoholic Steatohepatitis (NASH), represents a progressive form of metabolic liver disease closely linked to obesity, type 2 diabetes, and insulin resistance. This reclassification under the broader Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) framework reflects a shift toward understanding liver...

0 Commentaires 0 Parts 782 Vue 0 Aperçu

Connectez-vous pour aimer, partager et commenter!
Uttej Netha Ajouter une nouvelle offre d'emploi Health
2025-06-30 10:41:33

U.S. Dominates Global MASH Therapy Landscape with 43% Market Share
The North America Metabolic Dysfunction–Associated Steatohepatitis (MASH) Treatment Market is witnessing exponential growth, rising from USD 3.70 billion in 2024 to an anticipated USD 17.15 billion by 2033, at a strong compound annual growth rate (CAGR) of 19.3% from 2025 to 2033. This dynamic expansion is fueled by the increasing prevalence of obesity, Type 2 diabetes, aging population,...

0 Commentaires 0 Parts 813 Vue 0 Aperçu

Connectez-vous pour aimer, partager et commenter!